List of Abilify Maintena Kit drug patents
Abilify Maintena Kit is owned by Otsuka Pharm Co Ltd.
Abilify Maintena Kit contains Aripiprazole.
Abilify Maintena Kit has a total of 14 drug patents out of which 2 drug patents have expired.
Expired drug patents of Abilify Maintena Kit are:
- US9089567
- US8993761
Abilify Maintena Kit was authorised for market use on 28 February, 2013.
Abilify Maintena Kit is available in for suspension, extended release;intramuscular dosage forms.
Abilify Maintena Kit can be used as treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; maintenance monotherapy treatment of bipolar i disorder; treatment of schizophrenia, treatment of schizophrenia; treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia, maintenance monotherapy treatment of bipolar i disorder; treatment of schizophrenia; treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia, treatment of schizophrenia; use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia, treatment of schizophrenia, maintenance monotherapy treatment of bipolar 1 disorder; treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; treatment of schizophrenia, use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia; treatment of schizophrenia, use of aripiprazole in extended release injectable suspension; use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia, treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; treatment of schizophrenia; maintenance monotherapy treatment of bipolar i disorder.
The generics of Abilify Maintena Kit are possible to be released after 08 March, 2034.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8993761 | OTSUKA PHARM CO LTD | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) | |
| US8399469 | OTSUKA PHARM CO LTD | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9089567 | OTSUKA PHARM CO LTD | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(1 year, 5 days ago) | |
| US8759351 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Aug, 2023
(6 months from now) | |
| US8338428 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Aug, 2023
(6 months from now) | |
| US8722679 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(1 year, 8 months from now) | |
| US8030313 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(1 year, 8 months from now) | |
| US7807680 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(1 year, 8 months from now) | |
| US8338427 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Mar, 2025
(2 years from now) | |
| US11400087 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(10 years from now) | |
| US10980803 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(10 years from now) | |
| US11154553 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(10 years from now) | |
| US11344547 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(10 years from now) | |
| US10525057 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Mar, 2034
(11 years from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Treatment of schizophrenia; Use of aripiprazole in extended release injectable suspension; Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; Maintenance monotherapy treatment of bipolar i disorder; Maintenance monotherapy treatment of bipolar 1 disorder
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic